A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1335
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy ; day:4 ; month:2 ; year:2021 ; pages:1-11
Journal of cancer research and clinical oncology ; (4.2.2021), 1-11
- Urheber
-
Steidl, Eike
Filipski, Katharina
Zeiner, Pia S.
Wagner, Marlies
Fokas, Emmanouil
Forster, Marie-Thérèse
Ronellenfitsch, Michael Wilfried
Divé, Iris
Steinbach, Joachim Peter
Harter, Patrick Nikolaus
Bähr, Oliver
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-021-03511-y
- URN
-
urn:nbn:de:101:1-2021032812251932819742
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Steidl, Eike
- Filipski, Katharina
- Zeiner, Pia S.
- Wagner, Marlies
- Fokas, Emmanouil
- Forster, Marie-Thérèse
- Ronellenfitsch, Michael Wilfried
- Divé, Iris
- Steinbach, Joachim Peter
- Harter, Patrick Nikolaus
- Bähr, Oliver
- SpringerLink (Online service)
Ähnliche Objekte (12)
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
Glioma and temozolomide induced alterations in gut microbiome
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Perfusion and permeability MRI in glioma grading
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells
Feasibility of generalised diffusion kurtosis imaging approach for brain glioma grading
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
Glioma and temozolomide induced alterations in gut microbiome
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Perfusion and permeability MRI in glioma grading
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells
Feasibility of generalised diffusion kurtosis imaging approach for brain glioma grading
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
Glioma and temozolomide induced alterations in gut microbiome
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Perfusion and permeability MRI in glioma grading
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells